Icometrix adds $18M to coffers
Artificial intelligence (AI) software developer Icometrix has raised $18 million...Read more on AuntMinnie.comRelated Reading: Icometrix, Invicro team up on core lab imaging services Icometrix to collaborate with Siemens on AI for MRI Icometrix wins FDA clearance for brain CT AI software FDA clears Icometrix's dementia diagnosis software Icometrix announces launch of TBI commission
CONCLUSION: Our review suggests that MNPIs may improve the global, executive function and memory of PWD in NHs. The combination of exercise, cognitive training and activities of daily living, and intervention at least 3 times a week over at least 8 weeks with, at least 30 min per session using the integrated form is recommended for improving the global and specific cognitive functions of PWD in NHs. PMID: 31634894 [PubMed - as supplied by publisher]
DISCUSSION: Results suggest that combinations of nongenetic risk factors confer more risk for young onset vascular dementia, and possibly primary degenerative YOD, than a single factor on its own. Compared with their same-age peers, some people with YOD experience a lifetime of risk exposure starting from early in life. PMID: 31633559 [PubMed - as supplied by publisher]
CONCLUSIONS: The use of both prescription drugs and supplements increased over time, except for decreases in ginkgo and vitamin E. Prescription drug use appeared in line with prescribing guidelines. Supplement use was associated with higher education and better self-rated health; it persists despite a lack of supportive evidence. PMID: 31633558 [PubMed - as supplied by publisher]
DISCUSSION: These findings demonstrate that SMCs are associated with lower scores on objective neuropsychological measures among older AAs. Additional work is needed to determine whether SMCs are further associated with a risk for clinical transition to mild cognitive impairment or dementia among AA older adults. PMID: 31633556 [PubMed - as supplied by publisher]
The drug company Biogen Inc. says it will seek federal approval for a medicine to treat early Alzheimer's disease, a landmark step toward finding a treatment that can alter the course of the most common form of dementia
After declaring aducanumab a failure, the manufacturer now says the drug may help slow cognitive decline in certain patients. Some experts are skeptical.
Publication date: Available online 22 October 2019Source: NeuroscienceAuthor(s): Vanêssa Gomes Fraga, Carolina Antunes Magalhães, Cristina de Mello Gomide Loures, Leonardo Cruz de Souza, Henrique Cerqueira Guimarães, Danielle Alves Gomes Zauli, Maria das Graças Carvalho, Cláudia Nathália Ferreira, Paulo Caramelli, Lirlândia Pires de Sousa, Karina Braga GomesAbstractChronic inflammation contributes to neuronal death in Alzheimer’s disease (AD) and frontotemporal dementia (FTD). Here we evaluated inflammatory and pro-resolving mediators in AD and behavioural variant of FTD...
Authors: Mouton CP, Haas A, Karmarkar A, Kuo YF, Ottenbacher K Abstract Elder abuse and mistreatment (EM) continues to be a growing problem as the US population ages. Despite the growth, detection of EM continues to lag. However, Medicare claims data and the electronic health record might provide an opportunity to encourage better detection. We evaluated Medicare claims data from 2012-2014 for beneficiaries who had a diagnostic code for EM discharged from any types of facility. We extracted records for 10,181 individuals examining demographic characteristics, residential characteristics, residential location, type ...
Drug company says it will seek permission in the US to start marketing the potentially 'life-changing' new drug.